Skip to main content
SAMSUNG PHARMACEUTICAL.CO.,Ltd. logo

SAMSUNG PHARMACEUTICAL.CO.,Ltd. — Investor Relations & Filings

Ticker · 001360 ISIN · KR7001360007 KO Manufacturing
Open in API
Filings indexed 196 across all filing types
Latest filing 2022-03-21 Annual Report
Country KR South Korea
Listing KO 001360

About SAMSUNG PHARMACEUTICAL.CO.,Ltd.

http://www.sspharm.com/

Samsung Pharmaceutical Co., Ltd. is a company engaged in the research, development, manufacturing, and sale of pharmaceutical products. Its portfolio includes a range of medications, such as antibiotics and liver treatments, with a research focus on therapeutic areas like neoplasms. In addition to its core pharmaceutical operations, the company is also involved in the bio business and the sale of health foods.

Recent filings

Filing Released Lang Actions
사업보고서 (2021.12)
Annual Report Classification · 100% confidence The document is a 'Business Report' (사업보고서) for Samsung Pharm Co., Ltd. for the 68th fiscal year (2021). It contains comprehensive financial and operational data, including company overview, capital structure, business activities, production capacity, and asset status. This is the standard Korean regulatory filing equivalent to an Annual Report (10-K). FY 2021
2022-03-21 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a short regulatory filing (1580 characters) titled 'Audit Report Submission' (감사보고서 제출). It provides a summary table of financial data and audit opinions for Samsung Pharmaceutical as of March 15, 2022. According to the 'Menu vs Meal' rule, since this is a brief announcement of the audit report submission rather than the full audit report document itself, it is classified as a Report Publication Announcement (RPA). FY 2021
2022-03-15 Korean
매출액또는손익구조30%(대규모법인은15%)이상변경
Earnings Release Classification · 100% confidence The document is a regulatory filing from Samsung Pharm regarding a significant change (over 30%) in revenue or profit/loss structure. It provides key financial highlights, including revenue, operating profit, and net income comparisons between the current and previous fiscal years, along with the reasons for these changes. This is a standard regulatory disclosure required by stock exchanges for material financial shifts, fitting the 'Regulatory Filings' category as it is a specific disclosure announcement rather than a full annual or interim report. FY 2021
2022-03-14 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for Samsung Pharmaceutical. It outlines the date, location, and agenda items (financial statements, director appointments, and remuneration limits). This type of document is a standard proxy solicitation or notice of meeting, which falls under the Proxy Solicitation & Information Statement category.
2022-03-14 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal 'Notice of Convocation of the Annual General Meeting' (주주총회소집공고) for Samsung Pharmaceutical. It contains the meeting agenda, details on voting procedures (including electronic voting), director candidate information, and financial statements for the 68th fiscal year. This document is the primary material provided to shareholders to inform them of the upcoming AGM and to solicit their votes, which aligns with the definition of Proxy Solicitation & Information Statement.
2022-03-14 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea (often associated with the Financial Supervisory Service/KRX) used to solicit shareholder votes for an upcoming Annual General Meeting (AGM). It contains the agenda, director candidate information, and financial summaries required for shareholders to make informed voting decisions. While it contains financial data, it is not an Annual Report (10-K) or an Earnings Release (ER), but rather a proxy solicitation document sent to shareholders prior to the meeting.
2022-03-14 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.